Bristol Myers Squibb stock rallies 5.21% and outperforms competitors
Updated
Updated · MarketWatch · Apr 30
Bristol Myers Squibb stock rallies 5.21% and outperforms competitors
12 articles · Updated · MarketWatch · Apr 30
Shares closed at $60.59 on Thursday, with trading volume surging to 23.5 million, nearly double the 50-day average of 11.8 million.
The gain came as broader markets rose, with the S&P 500 up 1.02% and the Dow Jones Industrial Average up 1.62% in a favourable session.
Bristol Myers Squibb finished 3.65% below its 52-week high of $62.89, while it beat Johnson & Johnson, Pfizer and Abbott Laboratories on the day.
With BMY’s top drugs facing looming patent cliffs, which new therapies could realistically offset these losses and sustain growth?
Will regulatory changes like the Inflation Reduction Act and Medicare Part D redesign fundamentally disrupt BMY’s business model or create new opportunities?
How might Bristol Myers Squibb’s aggressive acquisition and R&D strategies reshape its future amid unprecedented industry-wide patent expirations?